MESOBLAST LTD (MESO) Form 6-K — Jul 9, 2026

$MESOForm 6-KFiled Jul 9, 2026, 9:33 PM ET0001345099-26-000064Original filing

Mesoblast Limited reported Ryoncil net revenue of US$36 million for the fourth quarter and US$115 million for the full year ended June 30, 2026, marking the product's first full year of commercial sales. Chief Executive Dr. Silviu Itescu noted that revenues have already exceeded initial projections, driven by strong uptake across major U.S. pediatric centers.

Key figures

Revenue: 115000000
Fiscal year end revenue: 115000000
Quarterly revenue q4 2026: 36000000

AI analysis

Red flags1 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.